Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | PTAFR | P25105 | 2/20 | 0.41 |
| ▸ | TYMS | P04818 | 2/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6387798 | 1.00 | MAPK14 (0.43) | MAPK14PTAFRTYMSNPY5RPARP1 | |
| SCHEMBL6385247 | 0.83 | MEN1 (0.42) | MAPK14PTAFRCYP11B2SMN1; SMN2CYP11B1 | |
| SCHEMBL6385244 | 0.83 | MEN1 (0.42) | MAPK14PTAFRCYP11B2SMN1; SMN2CYP11B1 | |
| SCHEMBL6387885 | 0.79 | MAPK14 (0.60) | MAPK14PTAFRTYMSNPY5RPARP1 | |
| SCHEMBL6387839 | 0.75 | CYP19A1 (0.40) | MAPK14TYMSCYP11B2CYP11B1CYP19A1 | |
| SCHEMBL6387841 | 0.75 | CYP19A1 (0.40) | MAPK14TYMSCYP11B2CYP11B1CYP19A1 | |
| SCHEMBL4037696 | 0.70 | MAPK14 (0.51) | MAPK14PTAFRCYP11B2CYP11B1CYP19A1 | |
| SCHEMBL4041628 | 0.70 | MAPK14 (0.70) | MAPK14PTAFRCYP11B2CYP11B1CYP19A1 | |
| SCHEMBL25295761 | 0.68 | HTT (0.49) | PTAFRTYMSPARP1PARP10SRD5A1 | |
| SCHEMBL18762883 | 0.68 | HTT (0.49) | PTAFRTYMSPARP1PARP10SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | MAPK14 4334/4885PTAFR 2761/4885TYMS 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.